In QUASAR Induction Study 1, patients who were not achieving clinical response at week 12 after receiving TREMFYA were switched to SC TREMFYA 200 mg. 1,c Of the patients in the TREMFYA groups who ...

QUASAR Phase 3 Induction Study Outcomes (Abstract #913b):1 Among 701 patients e randomized 3:2 to receive intravenous (IV) TREMFYA 200 mg or placebo at Weeks 0, 4, and 8, and observed through Week ...

Notably, those that had received guselkumab 200 mg IV in the induction portion then went to receive guselkumab 200 mg subcutaneously after week 12. Those in the placebo group were given 200 mg IV.

For a little bit of background, the phase III QUASAR induction study was a randomized double-blind, placebo-controlled, parallel-group, multicenter study of guselkumab, which is an interleukin-23 ...

In QUASAR Induction Study 1, patients who were not achieving clinical response at week 12 after receiving TREMFYA were switched to SC TREMFYA 200 mg. 1,c Of the patients in the TREMFYA groups who ...

According to Wehkamp, studies for Tremfya (guselkumab, J&J Innovative Medicines) in patients with inflammatory bowel disease are underway, including the phase 3 QUASAR induction study, the results ...

In QUASAR Induction Study 1, patients who were not achieving clinical response at week 12 after receiving TREMFYA were switched to SC TREMFYA 200 mg. 1,c Of the patients in the TREMFYA groups who ...

In QUASAR Induction Study 1, patients who were not achieving clinical response at week 12 after receiving TREMFYA were switched to SC TREMFYA 200 mg. 1,c Of the patients in the TREMFYA groups who ...

In QUASAR Induction Study 1, patients who were not achieving clinical response at week 12 after receiving TREMFYA were switched to SC TREMFYA 200 mg. 1,c Of the patients in the TREMFYA groups who ...

In QUASAR Induction Study 1, patients who were not achieving clinical response at week 12 after receiving TREMFYA were switched to SC TREMFYA 200 mg. 1,c Of the patients in the TREMFYA groups who ...

In QUASAR Induction Study 1, patients who were not achieving clinical response at week 12 after receiving TREMFYA were switched to SC TREMFYA 200 mg. 1,c Of the patients in the TREMFYA groups who ...

In QUASAR Induction Study 1, patients who were not achieving clinical response at week 12 after receiving TREMFYA were switched to SC TREMFYA 200 mg. 1,c Of the patients in the TREMFYA groups who ...